Cardiol Therapeutics (CRDL) Financial Statements
Cardiol Therapeutics Financial Overview
Cardiol Therapeutics's market cap is currently $139.88M. The company's EPS TTM is $-0.34; its P/E ratio is -4.71; Cardiol Therapeutics is estimated to report earnings on November 12, 2026, and the estimated EPS forecast is $-0.06. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 78.76K |
| Gross Profit | $ 0.00 | $ -373.11K | $ -248.35K | $ -219.91K | $ 78.76K |
| Operating Income | $ -34.32M | $ -40.28M | $ -29.79M | $ -50.34M | $ -45.47M |
| EBITDA | $ -34.21M | $ -36.30M | $ -27.88M | $ -30.71M | $ -38.44M |
| Net Income | $ -33.82M | $ -36.68M | $ -28.13M | $ -11.52M | $ -24.72M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 21.42M | $ 30.58M | $ 34.93M | $ 59.47M | $ 83.90M |
| Total Assets | $ 23.62M | $ 31.86M | $ 36.70M | $ 62.03M | $ 87.88M |
| Total Debt | $ 125.52K | $ 158.53K | $ 158.53K | $ 72.87K | $ 117.58K |
| Net Debt | $ -21.29M | $ -30.42M | $ -34.77M | $ -59.40M | $ -83.78M |
| Total Liabilities | $ 5.74M | $ 7.14M | $ 8.45M | $ 9.83M | $ 11.64M |
| Stockholders' Equity | $ 17.88M | $ 24.73M | $ 28.25M | $ 52.20M | $ 76.24M |
| Cash Flow | |||||
| Free Cash Flow | $ -23.88M | $ -25.08M | $ -25.25K | $ -27.30M | $ -23.56M |
| Operating Cash Flow | $ -23.85M | $ -25.06M | $ -25.18M | $ -27.22M | $ -23.55M |
| Investing Cash Flow | $ -24.48K | $ -21.29K | $ -64.31K | $ -74.71K | $ -12.92K |
| Financing Cash Flow | $ 15.54M | $ 18.84M | $ -55.38K | $ -53.93K | $ 93.44M |
Currency in CAD